Amgen

Darmiyan, Inc. develops a commercial diagnostic software platform for the early detection, monitoring, and stratification of Alzheimer’s disease and other neurodegenerative. It offers BrainSee, a Software as a Service (SaaS) platform that analyzes the scans and provides detailed brain maps with quantification of neurodegeneration in each voxel, as well as a summary score that reflects the person’s brain health and the likelihood of future cognitive decline. The company’s BrainSee is a virtual microscope of the human brain that takes standard clinical brain MRI and basic cognitive tests and generates brain maps and scores that indicate pathology at the earliest stages of the disease when treatments are feasible. The company was founded in 2014 and is based in San Francisco, California.

Keck Graduate Institute (KGI) is part of the prestigious Claremont college system, in Claremont, California. Keck is one of the few graduate schools exclusively dedicated to the study of biosciences. The school’s graduate programs blend academics with business-oriented approaches to the field. KGI awards master’s degrees, certificates and post-doctoral degrees in Biosciences and Biosciences Management. The school also offers degrees in Applied Life Sciences. Students receive a comprehensive education that integrates science, technology and management skills. Learning methods are also comprehensive and include scientific research and mentorship from outside professionals. Visiting mentors work in various capacities within the biosciences industry. This diverse education leads to diverse employment among graduates. Some of the areas in which graduates work include: * Medical diagnostics * Market research * Food technology * Medical writing * Pharmaceutical sales * Vaccine research * Biofuels development Admissions requirements include submission of transcripts, a resume, an essay, a personal statement and lists of references. Applicants are encouraged to apply for tuition fellowships, which can cover up to a substantial amount of KGI’s tuition. Students may also apply for federal loans. Federal loans require the FAFSA, while fellowships require a separate application. Keck Graduate Institute also honors the GI Bill, through which veterans may receive a tuition waiver.

As of 2015, all product rights to Prolia, XGEVA And Vectibix of GlaxoSmithKline plc were acquired by Amgen Inc. GlaxoSmithKline plc, All Product Rights To Prolia, XGEVA And Vectibix comprises the remaining rights of three pharmaceutical products namely Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Science 37 is making the promise of virtual trials the new reality. By engaging with patients from the comfort of their own home, the company provides access to patients who can never be reached by traditional site-based research models. Its virtual model has proven to enroll faster, retain patients at a higher rate, and reach a more representative patient population. Science 37 has conducted more virtual (or decentralized), interventional trials than any other company, using an expansive, in-house network of telemedicine investigators and home-health nurses. The company's research is powered by the industry’s most comprehensive, fully integrated clinical trial platform purpose-built to conduct virtual trials.

As of December 31, 2015, Catherex, Inc. was acquired by Amgen Inc.. Catherex, Inc. intends to develop Oncolytic Herpes Simplex Viruses program used for the treatment of cancer. The company is based in Philadelphia, Pennsylvania.

Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands. As of October 14, 2015, Dezima Pharma B.V. operates as a subsidiary of Amgen Inc..

Celimmune LLC, a clinical development-stage immunotherapy company, engages in treating and preventing immune mediated diseases. The company is based in Lebanon, New Jersey. As of November 30, 2017, Celimmune LLC operates as a subsidiary of Amgen Inc.

SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.

Honeywell's quantum computer uses trapped-ion technology, which leverages numerous, individual, charged atoms (ions) to hold quantum information. Honeywell's system applies electromagnetic fields to hold (trap) each ion so it can be manipulated and encoded using laser pulses.

Accure Health

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Generate Biomedicines, Inc. develops a platform to invent novel antibodies, peptides, enzymes, receptors, and other therapeutic proteins. It offers Generative Biology, a machine learning based solution that learns from all known proteins in order to encode and apply the fundamental principles of how genetic sequences lead to protein structure and function for creating novel protein sequences with optimized therapeutic potential. Its Generative Biology is applied to all protein modalities and generate novel proteins with desired functions and solutions that interact potently and specifically with therapeutic targets. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in March 2020. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Amgen Astellas Biopharma K.K. develops, manufactures, and sells pharmaceutical products. The company was founded in 2013 and is based in Chiyoda, Japan. Amgen K.K. was formerly known as Amgen Astellas Biopharma K.K.. As a result of acquisition of Amgen Astellas Biopharma K.K..by Amgen Inc., Amgen Astellas Biopharma K.K.'s name was changed. Amgen K.K. operates as a subsidiary of Amgen Inc.

Oxford Nanopore Technologies Limited develops and commercializes nanopore-based electronic systems for analysis of single molecules. The company offers MinION, a portable device for molecular analysis based on nanopore technology and is adaptable for the analysis of DNA, RNA, proteins, and small molecules; MinIT, an analysis and device control accessory for nanopore DNA sequencing; PromethION, a tablet-sized benchtop instrument that provides real-time data streaming; GridION system for molecular sensing applications; 109 cDNA Kits for its real-time and scalable sequencing technology that provides high throughput whilst generating complete sequences of full-length cDNA strands; and Flongle, a paradigm of smaller on-demand DNA or RNA sequencing tests with the potential to transform a range of applications where insights are required at low cost. Its devices are used in scientific research, personalized medicine, crop science, and security and defense applications. The company sells its products online. Oxford Nanopore Technologies Limited was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. The company was incorporated in 2005 and is based in Oxford, United Kingdom with additional offices in the United Kingdom, the United States, China, Japan, Germany, France, India, and Singapore.

As of November 20, 2019, Worldwide Rights to Otezla of Celgene Corporation was acquired by Amgen Inc. Worldwide Rights to Otezla of Celgene Corporation comprises manufacturing of oral and non-biologic treatment for psoriasis and psoriatic arthritis medicine business. The asset is located in the United States.

BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.

Nuevolution A/S operates as a biopharmaceutical company focused on developing drug treatments for human diseases within oncology and chronic inflammatory diseases. The company was founded in 2001 and is based in Copenhagen, Denmark. Nuevolution A/S operates as a subsidiary of Nuevolution AB (publ)

BeiGene is a clinical-stage Biopharma company focused on discovering and developing innovative, best-in-class, targeted and immuno-oncology drugs that address severe unmet medical needs in a variety of cancer indications.

As of September 30, 2016, ARO-LPA Worldwide And Exclusive License of Arrowhead Pharmaceuticals, Inc. was acquired by Amgen Inc.

eHealth Ventures is a consortium conceived to provide incubation services to promising early-stage healthcare technology companies in Israel. The Government of Israel offers a unique opportunity for leverage by providing significant financial incentives to incubators assisting technology start-ups capitalizing on Israel's extraordinarily rich talent pool. The next Tender is expected the second half of 2014. eHealth Ventures will apply for an eight-year license under the program. They are seeking qualified individual and institutional investors who would like to participate in this extraordinary, highly leveraged opportunity.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative, differentiated delivery systems for injectable drugs and vaccines.